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OBJECTIVES: To determine association between heart failure (HF) and in-hospital
mortality in ST-elevation myocardial infarction (STEMI) patients treated with Per-
cutaneous Coronary Intervention (PCI).METHODS: Retrospective analysis of I3 In-
Vision Data Mart (2003-08). Adult enrollees (18 years) with primary diagnosis of
STEMI were selected if they were a) treated using PCI procedure and b) had contin-
uous enrollment for at least 6 months prior to the STEMI-related index hospital-
ization (baseline). Enrollees were excluded if they underwent coronary artery by-
pass graft during index hospitalization. In-hospitalmoralitywas assessed based on
an algorithm using claims data (or lack thereof) for STEMI patients after index
hospitalization. Pre-existing HF was defined as presence of a claim with relevant
HF diagnosis at baseline. NewonsetHFwas defined as listing of HF as a comorbidity
in the reimbursement claims for index hospitalization without supporting evi-
dence for pre-existing HF at baseline. Multivariate logistic regression was used to
assess association between HF status and in-hospital mortality. Priori significance
level of 0.05 was used for these analyses. RESULTS: Overall 7261 enrollees were
included in the analysis. Out of these, 187 (2.6%) had HF at baseline and 1,075
(14.8%) experienced HF for the first time. Out of 7261 enrollees, 351 (4.8%) died
during index hospitalization. Chances of in-hospital mortality increased signifi-
cantlywith either pre-existingHF (absolute rate (AR): 9.6%, Odds Ratio (OR): 2.3, 95%
Wald confidence limits (CI): 1.0 - 5.4), new onset HF (AR: 10.7%, OR 3.0, 95% CI: 2.3 -
3.8) or inclusion of pre-existing HF as amajor comorbidity (AR: 16.7%, OR 3.9, 95%
CI: 2.2 - 6.9) in index hospitalization claims. CONCLUSIONS: Presence of HF, re-
corded as either a pre-existing condition or as a major comorbid condition, in
STEMI patients undergoing PCI was associated with significant increase in the
in-hospital mortality.
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OBJECTIVES: Lowmolecular weight heparins (LMWH) and factor Xa inhibitors (FXI)
are used to treat and prevent venous thromboembolic events (VTE) andmyocardial
infarctions (MI). Althoughhospitalized patients have increasedVTE/MI risk, almost
60% do not receive appropriate LMWH/FXI medication. Increasing LMWH/FXI uti-
lization while containing costs has become an important quality improvement
goal. Our objective was to estimate from the hospital perspective the annual inpa-
tient costs of increasing LMWH/FXI utilization.METHODS:We developed a budget
impactmodel incorporating event costs of deep vein thrombosis (DVT), pulmonary
embolism (PE), and MI, and pharmacy costs for two LMWH products (dalteparin
sodium injection and enoxaparin sodium injection) and one FXI (fondaparinux).
Inpatient event costs were estimated from AHRQ data at $10,000, $20,000, and
$9,000 for preventable DVT, PE, and MI events, respectively, and inpatient product
costs were estimated using 2010 wholesale acquisition costs with market-based
estimates of current product discounts. Changes in event, pharmacy, and total
hospital costs were estimated for a hypothetical 500-bed hospital in which LMWH/
FXI utilization increased from 60% to 80%, and market share followed two scenar-
ios: maintaining current LMWH/FXI share (90% enoxaparin, 0% dalteparin) or com-
plete formulary interchange from enoxaparin to dalteparin. RESULTS: Increasing
LMWH/FXI utilization from 60% to 80% with unchanged market share would de-
crease costs of DVT by $153,000 (5.5% reduction); PE by $25,000 (6.3%); and MI by
$12,000 (2.4%). Pharmacy costs would correspondingly increase by $308,000 (33.3%)
for a net increase in total hospital costs (event plus pharmacy costs) of $117,000
(2.5%). Alternatively, increasing utilization while also shifting product market
share to greater dalteparin and less enoxaparin use would reduce the pharmacy
cost increase to $208,000 (22.5%), for a net cost increase of $17,000 (0.4%).
CONCLUSIONS: Hospitals could potentially improve treatment quality by increas-
ing appropriate LMWH/FXI utilization, and by shifting utilization from enoxaparin
to dalteparin.
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OBJECTIVES: Different cost components (charges, costs, payments) are required to
estimate the economic impact of a drug therapy on inpatient care from a hospital
and a health plan (payer) perspective. To estimate different cost and payments for
acute coronary syndrome (ACS) inpatient care from different payer (hospital vs.
health plan) and benefit design [Fee-for-Service (FFS) vs. Prospective Payment Sys-
tem (PPS)] perspectives. METHODS: ACS discharges were identified using diagno-
sis-related group (DRG) codes using two data sources: 1) 2008 MarketScan admin-
istrative claims for health plan payments, and 2) 2008 Healthcare Cost and
Utilization Project Nationwide Inpatient Sample (NIS) for hospital charge data.
Admissions were classified as myocardial infarction (MI), unstable angina (UA), per-
cutaneous transluminal intervention (PCI), coronary artery bypass graft (CABG), and
stroke. Cost-to-charge ratios were used to estimate cost to the hospital. MarketScan
data were used to provide payments from payers based on different benefit designs
(PPS, FFS, Medicare and commercial coverage). Cost and payment components were
estimated at each DRG level and for individual ACS events. RESULTS: For ACS dis-
charges (NIS n109,903, MarketScan n85,962), an admission with both PCI and
CABG incurred highest hospital cost/plan payment ($43,867/$65,543) and UA in-
curred lowest ($4,369/$5,576). Hospital charges were consistently higher than plan
payments (e.g., PCI: $52,256 vs. $22,828), whereas estimated hospital costs were
consistently lower than payments (e.g., PCI: $15,902 hospital cost vs. $22,828 pay-
ments). Medicare payments were consistently lower than commercial payments
(e.g., PCI: $17,205 vs. $22,828). Detailed charges, costs, and payments estimates for
various ACS events will be presented. CONCLUSIONS: These ACS inpatient cost
estimates from hospital and health plan perspectives and for different benefit
designs will facilitate economic evaluations of ACS drug therapies. The analytic
approach demonstrated the feasibility and validity of using different secondary
data sources to estimate inpatients costs for various payer types and benefit de-
signs.
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OBJECTIVES: To examine the prophylaxis use, incidence of VTE, major bleeding,
minor bleeding and associated economic burden over 90 days in hospitalizedmed-
ically-ill patients.METHODS: A retrospective study (January 01, 2005 to December
31, 2007) was conducted using a subset of the MarketScan Hospital Drug Database
and its linked outpatient files from the Market Scan Commercial and Medicare
Supplemental database. Eligible patients were selected if they were continuously
enrolled in their health plan for at least 180 days prior to and 90 days following the
index hospital discharge date, which is hospitalization with amedically ill diagno-
sis. Prophylaxis use is defined as the admission date of index hospitalization to 30
days after index hospital discharge and before the date of their first VTE events.
Patients’ demographics, healthcare visits and costs were compared using Chi-
square testing and standardized differences. Risk-adjusted total healthcare costs
betweenpatientswith events andwithoutwere estimated using theGeneral Linear
Model. RESULTS: In patients who were identified as medically ill (n12,077), 6,464
(53.52%) received anticoagulant therapy during their hospitalization and until 30
days after discharge. Compared with patients who did not receive any anticoagu-
lant prophylaxis, patients who received anticoagulant prophylaxis had signifi-
cantly lower VTE events (1.47% vs. 3.58%, p0.0001). Although there was no signif-
icant difference in rates of major bleeding and minor bleeding, after risk-
adjustment for pre-specified covariates, patients with outcome events were
significantly associated with higher total healthcare costs (VTE: $40,523 vs. $17,698
p0.0001; Major bleeding: $27,430 vs. $18,137 p0.0001; Minor bleeding: $25,696 vs.
$17,410 p0.0001). CONCLUSIONS: Despite existing guidelines, few medically-ill
patients are receiving anticoagulant prophylaxis. Appropriate anticoagulant pro-
phylaxis use results in lower VTE event rates and total follow-up healthcare costs
in hospitalized medically-ill patients.
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OBJECTIVES: To compare mortality, healthcare utilization and cost burden of pa-
tients who suffered major bleeding during the 180 days after diagnosis of non-
valvular atrial fibrillation (NVAF) with patients who did not. METHODS: Based on
the 2005-2007U.S.Medicare advantage insurance claimfiles, patients aged 65 years
and older who have had two ormore primary diagnoses for NVAF occurring within
30 days of one another were selected. The 180-day follow-up mortality, healthcare
facility use and costs for patients with andwithoutmajor bleedingwere compared.
Risk adjustment was performed using the propensity scorematchingmethodwith
the ProbChoice™algorithm.RESULTS:Out of the patientswhowere identifiedwith
NVAF (n18,575), 266 (1.43%) suffered a major bleeding during the 180 days after
NVAFdiagnosis. Patientswere not significantly different in terms of gender, region,
and baseline comorbid conditions. After risk-adjustment for pre-specified covari-
ates, mortality (9.77% vs. 0.38% p0.0001), outpatient emergency room (ER) visits
(84.21% vs. 43.23% p0.0001), ischemic stroke (44 vs. 8/100 person years), myocar-
dial infarction (10 vs. 2/100 person years) and osteoporotic fracture (7 vs. 1/100
person years) were all higher for patients who suffered amajor bleeding compared
to those who did not. Besides inpatient costs ($26,568 vs. $8,929), risk-adjusted
outpatient ER costs ($1,280 vs. $744) were also higher for major bleeding patients.
The overall risk-adjusted difference in healthcare costs is significant ($35,691 vs.
$10,480 p0.0001). CONCLUSIONS: Most of the adverse events analyzed were
higher for patients who suffered a major bleeding after NVAF relative to patients
who did not. Total healthcare utilization and costs were also significantly in-
creased.
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OBJECTIVES: Tolvaptan is an orally administered selective vasopressin V2-recep-
tor antagonist for hyponatremia treatment. The Efficacy of Vasopressin Antago-
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